Fee-for-service hit discovery is backwards. OpenBench offers a simple solution. We bear the cost of virtual screening, synthesis, and experimental confirmation, so that the first dollar our collaborators spend is on potent, developable hit series. This success-driven paradigm fosters rigor, accountability, and operational efficiency. We construct hit criteria jointly with partners to ensure outcomes motivate further hit-to-lead pursuit. Once a deal is in place, our partners receive compounds in their labs in 2 months with validation soon to follow. OpenBench’s technology uniquely enables this success-driven paradigm. We manage scientific risk by picking hits from massive virtual libraries >100x more efficiently than conventional methods. Screening and judiciously filtering billion-compound libraries ensures novelty and developability of hits—traits conventional solutions cannot promise. To sign up for the OpenBench waitlist, please visit https://opnbnch.com
| Website | https://www.opnbnch.com |
| Employees | 8 (7 on RocketReach) |
| Technologies |
JavaScript
,
HTML
,
Twitter
+7 more
(view full list)
|
| Industry | Biotechnology |
| Keywords | Pharmaceutical Research, Drug Discovery, Pharmaceutical Development, Medicinal Chemistry, Drug Development Services, Virtual Screening, Preclinical Development, Biotechnology, Lead Optimization, Life Sciences, Collaborative Research, Compound Library, Synthesis, Small Molecule, Fee For Service, Outsourcing |
| Competitors | Intuit, Sage, Zoho, Xero, Tipalti, FreshBooks, Wave HQ, Bench Accounting, Expensify, Kashoo - Simple Cloud Accounting +38 more (view full list) |
Looking for a particular OpenBench employee's phone or email?
James Yoder is the CEO of OpenBench.
7 people are employed at OpenBench.
OpenBench is based in San Francisco, California.